Purdue Pharma, maker of OxyContin, expected to plead guilty to nation’s opioid crisis

The guilty charge is part of an agreement with the Department of Justice.

Purdue Pharma is expected to plead guilty on Tuesday for federal conspiracy and kickback charges and admits that the distribution of aggressive opioids has helped trigger an addiction crisis that has killed hundreds of thousands of Americans over the past three decades.

The guilty charge is part of an agreement with the Department of Justice. Critics say the company’s owner and a separate agreement with members of the Sackler family, who earn an estimated $ 10 billion from OxyContin, are too lenient as they don’t admit the violations and charge zero fees as part of the deal.

Purdue Pharma said it knowingly and deliberately offered salaries to health care providers to encourage them to write more prescriptions about their opioid products.

He also admitted that he assisted in the release of opioids without a legitimate medical purpose or a valid prescription, and did not provide accurate information about OxyContin to the Office of Drug Control.

Until it stopped distributing opioids in February 2018, prosecutors said Purdue sought to increase sales by sending sales representatives to prescription offices and pharmacies to deliver messages developed by the company, provide food and marketing materials, and provide prescription and prescription materials. about pharmacies that store Purdue opioids.

The settlement agreement quoted an executive who, in a presentation to Purdue’s sales supervisors in September 2010, said: “As I have said several times, we know that increasing the average number of customer calls has the biggest impact on everything you can do to increase Purdue’s recipes. with our main and super-core prescriptions. “

At an all-day trial at White Plains Bankruptcy Court in New York on Tuesday last week, a judge approved the deal between Purdue and the DOJ.